My name is Brent King. I'm the Chairman of the board of directors of Greenfern Industries, and it's my pleasure to welcome you here today. I'm advised that the correct notice of meeting has been given to shareholders and that the annual report has been made available to shareholders for the required period. We also have a quorum of shareholders, and hence we have a correctly constituted meeting. I now declare the meeting formally open and warmly welcome you to the first meeting, first annual meeting of Greenfern Industries since becoming a listed company on NZX. It's a significant stage for us now, a very significant event, and I want to personally congratulate Dan Casey. Congratulations, Dan. He is one of the founders of the company. He is our Managing Director, and he's made an amazing contribution to the business over the last 18 months plus. Dan, well done. It's great to get to this stage now and to be in our anniversary of our listing. Just to note, this is a meeting of shareholders. We have some non-shareholders here, and we welcome those who are non-shareholders. Although you don't have the automatic right to speak, we will try and include non-shareholders as much as we are able to do. We will seek to accept questions at the relevant times. If you do want to ask a question, please raise your hand, wait for the chair to acknowledge, and when acknowledged, please state your name and advise if you're a shareholder or a media person. Let me introduce some people. I've just mentioned Dan Casey. Dan. You'll hear from Dan shortly when he gives his full address to you. We have Kirsten Taylor, an independent director. Welcome, Kirsten. We have Marvin Yee, who's right behind me. Marvin Yee, welcome. Simon McArdle. Welcome, Simon. We have apologies from two directors. Mr. Philip Brown, Phil Brown, is not available for the meeting this morning. He has a personal matter to deal with. Mr. Darryl Davies, who resides overseas, Daryl is unavailable to join us today. We have our lawyer here with us, so welcome, Daniel. Daniel Wong from Flacks & Wong. We have Greg James representing our auditors from Crowe. Crowe did an excellent job for us this year. Thank you very much for your team. We have Hao Long, our CFO. Where's Howard? There he is. Hao Long, he's done our accounts, done a really good job for us. Of course, we have Peter Simmons, who's the author of an excellent appraisal report. Hopefully you've all seen our appraisal report, and if not, we can grab you a copy. For the papers you need today, you should have our notice of meeting, so that's the business we're going to deal with today. We will have Peter's appraisal report, and the screenshots will be available after the meeting, so the slides will be available on our website. We were due to have reps from NZX, and I want to personally thank them for what they have done. NZX have done a really good job for us. They come under a lot of pressure, and I put them under pressure previously in other listings, but this time they've done a really good job. I want to acknowledge their assistance and cooperation with us. We are fortunate to have Oliver here from the New Zealand Shareholders' Association, no doubt, we're gonna have some probing questions and some tricky things to answer later. Welcome, Oliver. Turning to the administration part, I advise that we have had lodged 72 proxies representing 29,662,885 shares, which is a total of 34.56% of the votes. We have proxies for 34.56% of the total votes. Do we have any apologies? Anybody put in their apologies? We have the first two that from Darryl Davies and from Phil Brown. Any other apologies? No. Okay. There being no other apologies, we'll move on to the business of the meeting. Dan, our Managing Director, will now run through the business and what we've done to date and give you an update. At the end of his presentation, we feel free to put up your hands and ask any questions you wish to have answered. Welcome, Dan. Tell us what we've done. Yeah. Thank you, Brent. Appreciate the introduction there and a little bit of an overview of what we are here for today. Yeah, good morning, everyone. Welcome to everybody who's been able to make it. It's a bit of an unknown for myself being our first shareholders meeting. It's great to see a bit of a turnout of shareholders and contributors to who we are today at Greenfern. It's been just a day over 11 months since Greenfern Industries listed on the NZX main board. We're listed under the GFI ticker. To be able to deliver our maiden annual shareholder meeting in person is a far cry from what we were able to do 11 months ago when we first listed. How times have changed quickly. The markets have changed, and the economic environment has also changed significantly since we listed. In the last couple of years, COVID has no doubt had effect on this change. These are uncertain times ahead, both globally for us at Greenfern, and but we're comfortable with the strategy and the direction of where we are headed. I'd like to play just a quick video clip about our why. We're at a point where it's time to take a stand to change the law. I've always admired the cannabis plant for over 30 years. Looking at medical marijuana, it's something that's affected my family, and I really wanna make it available for other families that find themselves in the same situation. When my first child, Theo, was three and a half years old, he had his first grand mal seizure on the couch. It scared me like nothing's ever scared me before in my life. At any given point, he could have up to 30 to 40 seizures during the day. He was diagnosed as intractable. So many extremely different solutions were presented, and we tried them all. I had to look at every aspect, every possibility, everything that I could do. We researched using cannabis for epilepsy. We identified that this plant could be utilized for epilepsy even though it was illegal here in Aotearoa. Once we started the cannabis oil, his seizures stopped. Right now, we have a normal family. Rekindled my passion in the plant. No going back now. Patients will tell you that cannabis works, and as doctors, we've got to listen to that. I've been a GP for 35 years and an addiction specialist for 10 years. I try and support patients. I try and educate doctors. People want their frustration with the current system to be acknowledged. That's part of my job, listening to them, listening to their concerns. At the moment, there are considerable barriers to providing a full range of medicinal cannabis products to patients. We are behind of what's going on in the rest of the world when it comes to cannabis, but we can utilize that as an advantage to watch what works and what doesn't work. I think New Zealand's got a wealth of expertise and experience in growing illicit cannabis. Let's put this to good use. I think, there's this great future for the industry here. By being able to do it in your own country shows traceability all the way back to every aspect of what goes into that medicine. There's greater gains to be had by looking at this plant as our friend rather than our foe. We're on the beginning of a road that's gonna be a long journey to help as many people as we can. Yeah, it still touches the heartstrings. TJ was an early part of our business. He's a longtime friend. He's a cannabis advocate, and yeah, his son, Theo, she's actually 12 years old now, an intermediate, still seizure-free and living a pretty good life. Yeah, it's just amazing, and that's just sort of a part of our why. Having endured the first 11 months of being a listed company, I personally reflect on it, and it doesn't seem like nearly a year has passed. Perhaps this is due to the immense learnings that we had in the public markets, as a startup company in a startup industry. However, we continue to be pioneers in this industry. We have a passion and a drive, and we're actually holding our own with our peers, and we're backed up with an experienced and well-versed governance level board. As I further reflect on the last 11 months, I'd like to recap on what it is that makes us a truly unique company with our fundamental value points and succinct points of difference that allow us to stand out in a sea of similarities. Yeah, look, we were founded in 2018. We're operating as emerging global leaders in a sustainable production of medicinal cannabis. We own our own on-site hydroelectric power station. This directly supplies the facility where we cultivate the cannabis and everything we do. The hydropower station is obviously at the core of our business. We've built a purpose-built and carbon neutral facility based around that. We also have operations spanning into the biotechnology, industrial hemp food, and body care spaces, although our main priority is medicinal cannabis. We're proudly New Zealand-based. We're branded, New Zealand-owned. We're Toitū net carbonzero certified, and we're also a B Corp business, and we're the only New Zealand medicinal cannabis business to have these two accolades, and obviously, we are listed on the NZX. What is it that gets us up every day with a drive to make a difference to not just our own but other people's lives, to be successful without compromising our environment, and to begin to add value to the region that has given us so much? We're proudly based out of Normanby South Taranaki, and here are some of the values that we hold close to us. Consumer health. Now, there's approximately 250,000 cannabis users for medicinal purposes in New Zealand, but a lot of this is supplied via the black market. The black market cannabis, you know, it's uncontrolled, it's unregulated. You don't know what's in it. You may think you are getting a positive impact from it, but, you know, fundamentally it's uncontrolled. What we do is we grow indoor medicinal cannabis. It's high quality, it's regulated, it's under a Ministry of Health license, and we plan to distribute those products both nationally and globally. We currently also have products that are distributed, manufactured under GMP in Australia. Sustainability is a big one in growing cannabis. Indoor is the most controlled way to be able to regulate the growth of the plant and have a consistent medicine. Growing indoors comes with the cost of high electricity prices, and it also has a carbon footprint. Because we have the hydro power station, we're able to eliminate that carbon footprint, use clean, renewable energy to do what we need to do growing in a controlled environment. Accessibility is difficult as well. There's low volumes of medicinal cannabis products manufactured in New Zealand, although that is changing, and if you follow the news in the industry, you'll see that. There's a lot of imported products currently in New Zealand, and we're hoping to help change that. As mentioned, we license GMP manufactured medicines in Australia, and we plan to bring those to New Zealand also. We want to look after the consumers, the patients, and the people of New Zealand as well. Taranaki, which is home to Greenfern, it's an economy that's traditionally reliant on dairy, oil, and gas. Being based there, we like to think locally, and we're trying to implement a new industry to the Taranaki region to diversify the successful businesses that are there currently. With the annual shareholder meeting being just that, an annual meeting, I'll now take a couple of minutes to point out some of the achievements that we've amassed to date over the last year and a half or so. We update the market regularly, and we also remain pretty active across our social channels, LinkedIn, Facebook, Instagram. But just in case you've missed them, here's a bit of a recap of some of our proud moments. Yeah, fundamentally, we purchased the hydropower station back in December 2020. A couple of reasons for this. Previous to that, we had a lease on the place, but having ownership allowed us full control and undisturbed control over that station. It was always part of the grand scheme of things, so yeah, we were lucky enough that the opportunity came up. It doesn't happen every day, and we were able to acquire that. May 2021, the first Toitū net carbonzero certified organization in New Zealand. We set out at an early stage to have that as one of our fundamental foundations, and we achieved that. June 2021, we teamed up with a company Hemp Connect and Callaghan Innovation. We obtained a grant through the BPA, which is the Bioresource Processing Alliance. We were looking again from a sustainability standpoint, looking for a use of what is a by-product in the processing of hemp seed. What we've discovered was there is actually a use from the hemp seed hull, which previously was just discarded as rubbish. 2021, we signed a master services agreement with Cannvalate. Unfortunately, Darryl, who's a co-founder and director of Cannvalate and a director of ourselves, he's not here today. He's unable to be here. That was a fundamental move. They have a big hold over the prescribing network in Australia, and early on, we targeted Australia as an early revenue market for Greenfern, while the New Zealand market was still maturing. October 2021, one of our biggest milestones to date was our compliance listing on the NZX. It was actually 11 months to the day yesterday. November 2021, we were announced as a winner of the Australian Cannabis and Hemp Industry Awards. We got the Green Award. That was voted by industry peers and our shareholders. 2021, we commenced distributing of GFI Pharma branded products. These are oil tinctures. They're manufactured under GMP in Australia by a contract manufacturer, and they're branded under our brand, GFI Pharma. In December 2021, we entered into a heads of agreement with Vortex. Now Vortex are a hydropower company based out of Rotorua. They specialize in upgrading, maintenance, and commissioning and building of hydropower stations. The power station being fundamental to what we do, we want to make sure that asset has the longevity and be part of Greenfern's journey. March 2021, we commenced the writing of clinical trial protocols in pursuit of the Australian over-the-counter low-dose CBD market, which is worth up to AUD 250 million. Cannabis being a regulated plant for so long, there's not been a lot of clinical trials, unable to do that. A lot of doctors rely on clinical evidence to be confident to prescribe these cannabis medicines. It's a fundamental reason why we're undertaking clinical trials to show that this plant does have efficacy, and it has safety data, and it is good for various indications. March 2021, or March 2022, sorry, we became New Zealand's first certified medicinal cannabis B Corp business. Again, we wanna do things the right way, and it forms part of our fundamentals from early on. June 2022, we received globally recognized GACP, which is Good Agricultural and Collection Practices. This is a requirement for growing and exporting cannabis in a flower form in New Zealand. June 2022, we secured a binding offtake agreement for two years, for the cannabis flower that we will grow, and that's into international markets. That's a big achievement for us. August 2022, just recently we entered a non-binding agreement to potentially supply Syndros, which is, one of only four FDA, Food and Drug Administration certified cannabinoid products globally. This is something we'll investigate further over the next three to six months. Just in September, this month, we were awarded a further grant, from the Bioresource Processing Alliance, and that's follow on from the initial findings from our earlier studies on the hemp seed hull, and it's really proving to have some, indications. I can't wait to get stuck into that and find what we can really do and how far we can push that. September 22, 2022, we received our export license from the Ministry of Health. Not many people know, but the testing requirements required for cannabis in New Zealand, there's no labs in New Zealand that can test for that cannabis, so you have to export it to be tested. In order to get an export license, you need to have met the minimum quality standards. It goes round and round in circles. We've got the export license with a reprieve to be able to export a certain amount so it can be tested to make sure it meets New Zealand minimum quality standards. It's tough. We're working with regulations that aren't the easiest to work with, but we're getting there. It's these achievements that create the foundations from which the company will grow. We've worked hard to build these foundations from quality principles of moral and ethical fundamentals so that we can endure strong future growth and prosper in the years to come. As we grow from our foundations that we have laid to date, we focus on how we can continue to grow the business and to generate consistent and strong revenue streams. We have a number of avenues for revenue at present, and opportunities knock often. However, I will now delve into these avenues a little deeper and explain the reasoning behind them. One of the key revenue channels for Greenfern is obviously cultivation and exportation of medicinal cannabis. We were issued a government commercial cannabis license in December 2021. This is up for renewal currently. We've had our recent inspection and there's no issues there. It's basically just going through the fundamentals and applying, paying the fee, and being given the new license. That has to be done annually. Currently, we have research and development and small commercial crop in our phase one pilot facility. We've had that facility going for about two and a half years now. Initially, we had a license for research and scientific purposes, which was the only license that could be issued at the time. Over those years, we've developed, you know, the fundamentals of where we are today. We've gone through different growing practices. We've trial and error. We've bred genetics. We've brought new ones in. We've stabilized genetics. We're at a point now where we're ready to scale. We have the phase II facility built currently, but the fit out requires further capital and hence you probably know we are looking at doing a on market capital raise shortly. Key takeaway, we're uniquely positioned to leverage critical offtake agreement, which we have in place, and to take a share in the growing market, both domestically and globally. GMP pharma. As I mentioned previously, we sell GMP medicines in Australia through prescribers, and we have New Zealand as a target market. With our successful move into the patient acquisition and prescriber space in Australia, this was through Cannvalate. Our first prescriptions were back in October last year, and to date we've yielded, yeah, pretty strong growth actually. 31% new patient growth month-on-month, and we have a returning patient percentage of 27% month-on-month. Before we went into that, we modeled a lot of different models, and the one we landed on was a 10% return patient rate. That's what we based our models on. We're surpassing that, and it's pleasing and it's growing. The Australian TGA standards are strict, but this will assist in bringing these medicines to New Zealand. We're able to distribute them there. Obviously, New Zealand is a smaller market and the minimum quantity of units that you need to get manufactured is quite high, and they have a certain amount of shelf life. Having the ability to move a lot of units in Australia and bring the amount needed to New Zealand's smaller market was always a plan. That's the next step is to do that, bring them to New Zealand. Touch on Syndros again. It's one of four globally FDA-approved cannabinoid medicines. We're looking at a 10 + 10 year to license this medicine for Australia, New Zealand and the Pacific Islands. Currently this being FDA- approved has an on-label indication for chemotherapy-induced nausea and vomiting and AIDS-induced anorexia. As more people undertake clinical trials, and we may do ourselves, the Syndros medicine will come with more on-label indications and open up a larger total addressable market. This is something that we need to look at in the future, enter a binding contract if our shareholders decide to do so. The board as well. Key takeaway for this, we see the larger and more advanced Australian market to be a key growth driver, and we're working towards securing significant licensing agreements for Australia as well as New Zealand and the Pacific Islands. Clinical trials. As I touched on, clinical trials are essential for proving the efficacy and safety of medicines. Doctors are hard-pressed to prescribe without that clinical data. We teamed up early on in the piece about a year ago with iNGENū, which is a contract research organization based in Melbourne. After the TGA announced that they will be down scheduling from a Schedule IV medicine to a Schedule III low dose or less than 150 milligrams per day of CBD medicine. We're about 90% through writing the clinical trial protocols, and if anyone's ever been involved in that, there's a hell of a lot of work. Schedule III products, they require TGA approval and ARTG listing, which is the Australian Register of Therapeutic Goods. Basically, once you've gone through the clinical trial process, and you've met all your endpoints, and the medicine does what it says it's going to do, then it becomes a registered medicine, and doctors can prescribe that on label for a specific indication. In our case, we're targeting anxiety, mild anxiety. Being over the counter, it has to be self-diagnosed. It can't be, you can't be referred by a specialist, et cetera. If anything, over the last couple of years, anxiety's probably a little bit more prevalent in the world than it was prior to that. I guess a key takeaway from that, we're increasing our presence in the biotechnology and clinical research space. Aided with our new partnerships with Cannvalate and iNGENū in Australia, we're moving into the world of being a cannabinoid manufacturer. Last one here, electricity generation. As mentioned, we entered a contract with Vortex Group, and basically, this is for us to upgrade the hydropower station, turn it from what it is now, which is an older hydropower station, obviously functioning. We've put a lot of effort into getting it to that stage. To bring in Vortex, they will upgrade at their cost, which is probably a couple of million New Zealand Dollars worth of input. They'll manage the entire upgrade, and at the end of it, instead of having a book value of, you know, NZD 750,000-NZD 800,000, it'll be worth approximately NZD 350 million, NZD 3.5 million, and the kilowatt capacity that it can generate will go from 250 kW up to around 950 kW. Basically, that's about a 3.5x increase in power generation. While we'll only own 50% of the asset, and we'll share the other 50% with Vortex, the book value will still be worth more, and we will still have a lot more power than we could ever need at our facility. Obviously, with getting the cost price power, we can grow our cannabis for a lot less than other people, and we also sell excess power back to the grid. There's a couple of revenue streams there. Obviously, the hydropower plant is a meaningful differentiator, both environmentally in terms of manufacturing costs. Now to touch on some of our financials at a glance. I'm sure you've all had a look at our annual report, and I must point out that we are a startup. We're a startup business in a startup industry. Having revenue is a key driver for us, obviously, but we still need to be capitalized to get to the point where we are revenue positive, and we have a clear path for that. Yeah, just if we look at the revenue last year versus this year, you can see it's increased, and it's continuing to increase. A lot of this is from Australian GMP pharmaceutical cannabis oil sales, and it does fluctuate, but the trend is upwards. Our gross profit as well is on an upward trajectory, and we hope it to continue that way. The final slide there, just GFI Pharma sales. You can see we kicked them off in October last year, and they're growing incrementally. Yeah, this is one area that we'll look to increase. We're in talks with other prescribing networks, doctor networks, and pharmacy networks in Australia, and then we'll look to bring these also to New Zealand. Without dwelling too much on the numbers that are based in the annual report, we're focusing on looking forward and growing all of these areas. To summarize, our first year as being a listed company, it's been a journey of learning, of discovery, and of growth, and we're definitely better for it. We're well-placed for future growth over the coming years. We're more robust. We have clear direction. We have solid plans, but we still do require the backing of our shareholders to enable us to realize this next stage of growth. We listed in part to have access to the capital that public markets can provide. We've not yet been to the market for capital since listing in October 2021, nor did we IPO at that stage. We became a listed company to not only provide a form of liquidity for our early shareholders but also to attract a new and stable shareholder base in the public market moving forward. Shareholders that can envisage and share the journey to success with us. As we transition to the next stage in this very much new medicinal cannabis industry, both here in New Zealand and further afield internationally, we're excited to have you, our shareholders to join us and help us to realize the full potential and the success for us all. Yeah, any questions, from the floor out there? I'm happy to answer any, unless they're difficult. You mentioned hemp seed. That there's some potential there. Can you elaborate more on that? We're using various methods to bring these lipids, oils from within the hemp seed hull itself or the shell. I won't tell you how we're doing it 'cause that's a bit of a secret. What we're finding is antioxidant and anti-aging properties in this. We got to the end of the first years' worth of research with Callaghan, and they were pretty excited. If you've worked with scientists before, for them to get excited is quite the thing 'cause normally they're quite dry. They were excited and, you know, they were talking, do we look to bring in a commercial partner? You know, antioxidant, anti-aging, this is something that could potentially go into, you know, a face cream, night cream, could be the next Oil of Olay, whatever it is. We decided, no, let's refine it further. Let's get more knowledge, get some actual clinical testing data on this, so we have proof of what it actually is capable of, and it's really exciting. Yeah, they rushed that through. We got the next grant, and yeah, we're about to kick off the next 16 months of study into this and what it brings is I'm excited. Yeah. Yes, gentlemen. It's a crowded field out there, certainly in the listed space. You've got yourselves, Rua Bioscience, Cannasouth, and there's probably a host of unlisted companies as well. First part of the question is how will Greenfern differentiate itself compared to its competitors in the New Zealand market? The second is, to what extent, and you talked about the regulatory issues that the industry is facing as a whole. To what extent do you need to work on behalf of the sector as a whole and balance that with Greenfern's development? How is that balance between working with the competition and supporting Greenfern's unique place amongst the competition? Yeah. Thank you. Good question. Yeah, essentially, it is, I guess, a crowded space in terms of licenses that have been issued in New Zealand for medicinal cannabis. I think there's about maybe 30. There's not many growing indoors, and basically, the cost of growing indoors is very expensive. When you're dealing with pharmaceutical-grade flower medicines, you need the exact light consistency every day, the same relative humidity, the same temperatures, the same consistency throughout the whole life cycle of the plant in order to get that finished flower product, so when it goes on to be prescribed as a medicine, it is exactly the same each and every time. Now, there's no real set cost of what the power consumption is, but it's somewhere between about 20%-60% of your OpEx is electricity growing indoors for cannabis. Now, we put a cost against the cannabis that we grow of about NZD 0.08 a kilowatt. It doesn't cost us that. We just have to pay for the operating expense of running the power station, which is about NZD 0.01-NZD 0.02 a kilowatt. When you plug in at home, turn your lights on, you're paying anywhere around NZD 0.29-NZD 0.35 a kilowatt. It's a heck of a discount. We can, and we've got the metrics there of what we can grow a gram of cannabis for, and it's very competitive globally, even with some of the larger outdoor growers. Now, growing outdoor, you can grow a lot more cannabis, but you're relying on the sun, the weather, and generally, that cannabis grown outdoor is grown for the extraction market, and it's refined and turned into oils, tinctures, et cetera. We're targeting the medicinal flower market, which is one of the fastest-growing markets, globally. We sit on the New Zealand Medicinal Cannabis Council, so collectively, a lot of the larger cannabis companies are part of that. What we have been doing for the last year and a half is trying to lobby the Ministry of Health and their regulations because fundamentally, there's parts of it that don't work. Now, we've got the highest regulatory standard in the world. It's GMP Plus. It's tough. From my standpoint, I think it's easier to start high and then lower the bar than start low and go, "We've buggered it up. We need to raise it." We're going in the right direction, but, yeah, like most government agencies, it's a slow-moving ship. Yeah, we're obviously lobbying for change, and there are some new regulatory changes coming, so we're all waiting with bated breath to see where that lands. I've talked about the testing of the cannabis not being able to be done in New Zealand just earlier. There are labs that are moving towards being able to do that. It's only about a half dozen tests that can't be done or so. Yeah, in the next sort of year, we should see labs capable of being able to do that. I mean, going back earlier on in the piece, before we were listed, we teamed up with a quite a well-known company from the U.K. They're one of the largest suppliers of CBD API, which is the active pharmaceutical ingredient within the CBD oil. We tried to bring that in through the New Zealand regulations, and we couldn't, basically one of the tests was done under U.S. Pharmacopeia and not European Pharmacopoeia, so it wasn't allowed. Now, those two testing standards are almost identical, but one has U.S. before it, one has E.U. It's tough. It's gonna affect a lot of smaller companies to try and meet these standards and the regulatory standards, hence why we listed to become stronger, to get a better access to capital, and to get quicker growth and really put ourselves out in front, ahead of everyone else. Yeah, there's a number of companies that we work with together, and I think in the future you're probably gonna see more collaborations and co-ops and stuff like that. Yeah, hopefully that. Great. Thanks. Thank you. Anybody else? To follow on from that first question, obviously for indoor growing it's a control thing, but what are some of the risks, apart from weather, things like that, with growing outdoors? If I'd brought one of the certificates of analysis here today of some of the flower we grow, there's about four different pages of different pesticides and heavy metal tests. There's literally hundreds and hundreds of different tests that you test for. Growing outdoor, obviously you've got pests, you've got environmental things that go on. You're growing in soil, there's pathogens in soil. If you get any sort of contamination or infestation in your plant, you've got to spray it to, you know, bring it back to life, and then your plant may not test up to the minimum quality standards. Growing indoor, while it is heavily reliant on electricity, we have no bugs, we have no pathogens, everything's controlled. We have air sterilization systems in place. Yeah, we're putting ourselves in the best chance that we can because we are able, with the low-cost power, to make sure we meet those minimum quality standards. No more questions, I'll hand it off to our chairman. Thanks, Dan. That's very good coverage of what we've done in the year. You can see that Dan's been very busy. I was a bit negligent earlier. I forgot to raise John Hussey's role in the company. John is a fellow founder of the business. He works in the company. He's Head of Growth. John is in Germany now. Germany is our first area we're hoping to be able to export our cannabis to. He sends his apologies also. John and Dan have set up the company and made it work. John is the biggest shareholder, and rather than be here, he's out there trying to sell us some cannabis into international markets. Don't think Dan's doing it all, but he's certainly doing a lot, and John's very important to the overall balance of the company. We can ask questions subsequent to this, but let's go through the details of the business now. Our representative from our auditors, Mr. Greg James from Crowe, has left the room, so we can deal with how we pay him now. Under resolution one of the agenda, you'll see that the resolution is that the directors of the company will be authorized to fix the fees and expenses of Crowe New Zealand Audit Partnership as the company's auditors. I move the resolution. Do I have a seconder for that? Yeah. Thanks, Kirsten. Do we have any discussion on that? I'm very pro what Crowe have done this year. They've been outstanding. They got through the work. Always hard to do your first audits, so they plowed through it, got it in on time, and they were really good to deal with. From our side, we endorse them remaining as our auditor, and we'd like to set the fees. We of course will be as tough on their fees as other fees. We'll be ensuring we don't overspend. Anybody like to ask any questions on that? No? If there are no questions, I'll put the resolution. All in favor, please say aye. Aye. Aye. Those against? I declare the motion carried. We move to resolution two, which is the election of Daniel Casey. You've seen Dan do his stuff. You will have the information on Dan. Dan, do you want to add anything to this? Yeah. No. I'm just a good guy. Please. I enjoy what I do, so yeah. I think he's. All in your hands. Thank you. Just to make a comment on Dan, I think he's got about one and a half law degrees with the amount of law he's had to learn over the last little while in conjunction with Daniel Wong, and also lots of those things to satisfy to get the product through. I propose the motion. Do we have a seconder? Mr. Yee behind me. No further discussion? I put the motion. All in favor, please say aye. Aye. Aye. Those against? I declare the motion carried. I move to resolution three, the election of Kirsten Taylor. That Kirsten Taylor be elected as a director of the company. I propose the resolution. Do I have a seconder? Yeah. Thank you, Marvin. I'll give it to you in a sec, but I'll just make a comment on that. Kirsten has been a big assistance to the board. She brings an understanding of a lot of things that us boring accounting-type people and legal people don't understand, and she brings a diversity not just in gender, but very much in understanding of starting new businesses, particularly in this sector. The benefit for us is manifold. I endorse Kirsten very strongly. Kirsten, can you tell us a bit more about yourself? Yes. Hi, everyone. I'm Kirsten Taylor. I'd like to seek reelection to the GFI board. As a business owner, I have understanding of the challenges that come with growing a business, and I'd like to share my experience in governance, business, and marketing to contribute to helping make the strategic plans of Greenfern Industries a reality. On a personal note, I've never been so scared as when my family member had a seizure. Because I'm a qualified medical herbalist, I was fortunate enough to be able to stop the illness. Cannabis is an extremely valuable medical herb that will transform the lives of many people and simply needs to be available for everyone who needs it. I believe Greenfern Industries is a very special company, and I'd like to continue to support them as a shareholder and a director. Thank you. Thanks, Kirsten. Do we have any questions for Kirsten? Kirsten, if I may just allude to your day job. Do you wanna just tell us what you do day-to-day? Well, I help people sleep. My company is SleepDrops. I invented a range of fantastic sleeping products many, many moons ago when I was working as a naturopath, helping infertile couples become families. I realized there was a serious link between insomnia or poor sleep and general health, and I started to create formulations that would help change the sleeping patterns of those people to establish health. Then fertility came naturally. From that, I became completely mad about sleep and researched everything there was, and I am truly convinced it's the foundation for all health and well-being. I've been very lucky to be able to help New Zealand sleep for 13 years and as number one brand up against all the big guys. Even without their multi-billion-dollar marketing budgets and teams, we're still holding our own, and I bring all of that guts to help GFI as well. Thank you. Thanks, Kirsten. Where can we buy your product? Everywhere. We, all in favor, please say aye. Aye. Those against, carried. I'm turning to resolution four, that Marvin Yee be elected as a director of the company. I propose the resolution. Do I have a seconder? Yep. Two. Thanks, Kirsten. So, Marvin's a long-term friend of mine. I've known him over a long time. He's an active investment banker, capital raiser, and he's done lots of transactions around. He's been very good to our board here, and he's a valuable addition. Marvin does travel a lot, so he does bring quite a lot of different ideas back from overseas. I just slipped him a note before to ask him to tell us a little bit about another country that's deregulating, and that's Thailand. It's quite interesting to think about what has been happening in an area where if you've ever gone to Thailand and Malaysia and Singapore, you have death. The drug traffickers sit right above where you pick up your luggage, and it's quite scary on that side. Things are changing there. Marvin, if you could tell us a little bit about yourself and a little bit about what you've experienced in the last little while. Hello, everyone. Yes, I'm Marvin Yee. I'm the principal for Grant Financial Services. We are a private equity group with operations here in New Zealand, United States and Singapore. We've got over 98 portfolio companies globally. One of the key, including cannabis interests in the United States, Colombia, and of course here in New Zealand. It's a key investment consideration of ours when we look at companies to ensure that they are in a high-growth industry. Over here, cannabis is what we see here is, we do believe that we are at the ground floor with this. The thesis being that if we could invest in, say, in the New Zealand context, a Trade Me, you know, before they were acquired by Apax Partners or Uber before they became as big as they were. You know, these are industries which we know are gonna work out, and it's just a question of, it's really just an execution risk more than a market risk. Now as we look at cannabis with the deregulation across, that's happening in many places, we are very much in this sort of position. As Ben pointed out, I was in Thailand just recently up until last Sunday. On the 9th of June, Thailand had decriminalized, became the first nation in Asia to decriminalize cannabis. On that day, they released 4,200 prisoners. They're not going back. It is truly quite amazing for this to occur in a really very conservative country where for the most part would have probably just thought of them, when we think about Thailand and drugs, images of the Bangkok Hilton movie probably comes to mind. Being there now, we've seen that there is such a transformation that has occurred in the areas where tourists are. There are cannabis dispensaries virtually almost in every corner. It is widely available. There is talk of regulating it somewhat because the quality does vary. However, it is an area now that's going through an immense amount of growth. I can't help but feel that this is probably going to be a blueprint for many other places in the world. Certainly, when we look at Greenfern and what we are trying to do, and with the fact that we are already starting to import across to Germany and of course to Australia, we have been selling in Australia, there is a distinct optimism I have in this company that this will become that next great big thing, like the Trade Me's, like the Uber's. You know, there is certainly the market opportunity for that. It is just merely a question of whether we have the execution to be able to accomplish it. I'm very excited to be here at the board, and thank you. Just a couple things. How many boards are you on? Just, like, no doubts with your credibility, but will you have the time to dedicate to Greenfern and the relationship with its shareholders going forward? Well, I think that stemmed from the statement I made earlier on about having about 98 portfolio companies. That is true. I am not on the board of 98 companies. I am on the board of approximately six companies. Thanks, Marvin. Any more questions? There being no more questions, I put the resolution. All in favor, please say aye. Aye. Those against. Carried. Also, on voting, you will all have your voting cards, and you'll have to fill those out. The voice is only indicative, but we need you to fill out your voting cards at the end of it once we've gone through all the different ones. It is in your hands. Computershare will tell us after the event as to the outcome of each of the resolutions. Turning now to resolution number five, that the current maximum aggregate amount of remuneration payable by the company to directors of NZD 350,000 per annum may, at the board's discretion, in whole or in part, be through an issue of equity securities as that term is defined in the listing rules in the company, provided that the issue is in compliance with Listing Rule 4.7. Now, we do have Daniel here to explain our legal counsel. Does anybody wish to ask any questions on that? Hey, Oliver. Daniel, are you free to take that? I may need assistance on anything. It is a question for clarification only. Yep. Talk to me, just to be clear, if any equity is paid instead of cash, is that included within the director's fee pool? Yes. It is. It is. It's either cash or shares. It's not cash and shares, increasing it past the total. I'd just like to thank Greenfern for their communication and keeping us all. Oh, excellent. Thanks, Oliver. I think everybody can see how active our Shareholders' Association is, and I think they act in good regard for individual shareholders. I think they play a very good role for individual shareholders. Thank you. All in favor, please say aye. Aye. Those against. Carried. I think this is quite a good thing after the event in where we are able to conserve cash within the company and shows the support the directors have for the company by taking shares in lieu of cash. Turning now to. Sorry, I should have noted there, the directors are not able to vote on that, so they know that. Just in case you're wondering, the directors present are not able to vote on something that affects their own circumstance. Resolution six, the extension of the Cannvalate agreement, and we have an agreement with Cannvalate. They provide us with the oil that we sell each day, each week in Australia. We wish to extend the arrangement we have with them. Would anybody like a greater description of that? Dan talked about it earlier. We have notes in the notice of meeting that explains that. We've put the resolution. You'll still have to tick it, but we put the resolution as on the board and as in your notes. All in favor, please say aye. Those against. Carried. A rights issue. Issue of shares pursuant to a rights issue. That for the purposes of Section 129 of the Companies Act, the shareholders approve the issue of up to NZD 5 million of new shares pursuant to the rights issue on the terms set out in the accompanying explanatory notes, which require an issue price not lower than a price equal to 50% discount to the 30-day VWAP price prior to the rights issue being made in consideration for and terms of the issue to be, in the board's opinion, fair and reasonable to the company and to all existing shareholders. It's clear that the board has to believe that it's fair and reasonable to the company and to all existing shareholders. Do we have any questions? Okay, you still have to tick the boxes, but I put the resolution. All in favor, please say aye. Those against. Carried. Anybody want to ask any questions or talk generally about the business or where we've got to and where we're going? If you are heading down to Normanby to the Taranaki, New Plymouth area, please let Dan know. It's certainly worth going and having a look, and it's interesting to actually see the plant grow and to look at the power generation facility and just to see how it all ties together. It's quite a nice afternoon if you have time to pop down and have a look at some point. Please contact Dan. Advisors, thank you for coming, and sorry we haven't utilized your skills. Daniel, anything else you think the meeting should know? Votes will be counted, all according to a poll per listing rules, and an announcement of results will be made via NZX, as soon as practical after the meeting. Excellent. NZX uploaded a photo of the board and some things they did for us yesterday to celebrate our listing. If you get a chance, go on NZX and you'll find some info there. For everybody, thank you very much. Thank you for coming along. You're very welcome to stay and have a coffee and a chat to each or all of the directors. Thank you for taking the time. Have a good day.